Although the upregulation of ACE2 has been reported in COPD lungs by several studies, to the best of our knowledge, this is the first study that investigated the levels of ACE2 in the lung parenchyma, airways, and vessels of ever- and ex-smokers and patients with COPD who died from COVID-19. This evidence concerns the gene ACE2 and COVID-19.